2015ESC急性心衰患者早期管理指南述评

2015-06-30 张健 摘自:365医院网

作者简介:张健,医学博士,主任医师,教授,博士导师。国家心血管疾病临床医学研究中心副主任,中国医学科学 导读:2015年5月21日, European Heart Journal 刊发了由欧洲心脏学会(ESC)心力衰竭委员会、欧洲急诊治疗学会和流行病学急诊治疗学会联合制定的《急性心力衰竭院前和院内管理指南》。这项指南实用性强,针对急性心力衰竭(AHF)的定义、院前早期处理、入院评估、实验室检查、器

作者简介:张健,医学博士,主任医师,教授,博士导师。国家心血管疾病临床医学研究中心副主任,中国医学科学

导读:2015年5月21日, European Heart Journal 刊发了由欧洲心脏学会(ESC)心力衰竭委员会、欧洲急诊治疗学会和流行病学急诊治疗学会联合制定的《急性心力衰竭院前和院内管理指南》。这项指南实用性强,针对急性心力衰竭(AHF)的定义、院前早期处理、入院评估、实验室检查、器械治疗、药物治疗、院内治疗等多方面进行了比较具体详尽的阐述,更加“接地气”。以下初步解读一下新的指南。



1. 急性心力衰竭(AHF)通常指初次发生的或慢性心力衰竭(CHF)的症状和体征迅速恶化,同时伴有脑利钠肽(BNP/NT-proBNP)升高的临床情况。首次将BNP/NT-proBNP纳入了定义。

2. 急性冠脉综合征(ACS)导致的AHF,应突出“及时治疗”的理念。其他因素导致的AHF也应尽可能早的接受治疗。

3. 对处于院前阶段的AHF患者,下列措施能带来早期获益。如:早期(如急救车内)即无创监测,包括脉搏血氧饱和度、血压、呼吸频率及连续心电监测等;若氧饱和度<90%,应及时进行氧疗;无创通气也是呼吸窘迫患者的早期治疗措施;根据患者血压情况和/或充血程度决定血管扩张剂、利尿剂的应用;尽快转诊至附近有完备心内科和/或CCU/ICU的大中型医院。早期行利钠肽检测也将带来益处(包括指尖测利钠肽)。一旦患者进入急诊/CCU/ICU,需立即同时开展确诊和治疗工作。

4. 完善入院临床评估及临床调查。对于疑似患者,要及时评估呼吸困难的程度、血流动力学状态及心律,记录:

(1)呼吸困难严重度,包括呼吸频率、是否能仰卧、呼吸力度及缺氧程度;
(2)血压(舒张期及收缩期);
(3)心律及心率;
(4)体温情况,是否存在低灌注征象(如四肢阙冷、脉压变窄或精神淡漠)。
(5)对以上问题要反复评估,则有利于AHF的治疗和诊断。

5. 注重基本检查,如:心电图,实验室检查(cTn、BNP/NT-proBNP、Cr和BUN、D-二聚体、血糖、血常规等),床旁X胸片、超声心动图等。有助于了解患者病因。特别突出指出,患者应每1-2天复查Cr和BUN、电解质、BNP/NT-proBNP,重症患者要注重监测。

6. 对护理也提出了具体要求。提出了:

(1)要有安全适宜的诊治环境;
(2)客观记录患者的治疗反应和相关症状和体征;
(3)合理制订出院计划或转诊至多学科疾病治疗部门。

同时要注重对患者的心理辅导和与家属的恰当交流。严密监测患者的病情变化并及时与医生沟通。

7. 对氧疗及辅助呼吸要点做出了具体指导。

(1)使用血氧饱监测SpO2。
(2)入院后评估患者血液酸碱度,尤其适用于急性肺水肿或COPD病史患者。
(3)若SpO2<90%,应考虑氧疗。

在中度的心衰的病人当中就可以检测到SpO2的下降,根据需要FiO2可以提高到100%;并根据SpO2调整。对于呼吸困难明显的患者,特别提出了应尽早使用无创通气治疗,甚至在转运途中,就应该尽早应用,并推荐了PS-PEEP模式。

8. 为了改善症状,指南提出要早期给予利尿剂和血管扩张剂。起始即静脉注射呋噻咪20mg至40mg,对急性失代偿的患者则起始剂量不小于既往最大的口服量。若患者收缩压正常或偏高(SBP≥110mmHg),可以予静脉注射血管扩张剂。此外需要说明的是,静脉利尿剂的最佳剂量及给药时间尚无明确足够的指导依据。指南建议在合并快心室率心房颤动的AHF患者中,可以静脉注射强心苷类药物,此时,β受体阻滞剂也是一线推荐用药。

9. 在AHF中应慎重使用的药物(不包括心源性休克)。

(1)不推荐将阿片类药物作为急性心衰常规用药;
(2)指南指出,对于SBP>110mmHg的病人,没有指征使用缩血管药物;同时,当低心排血量改善以后,血压稳定,就应停用拟交感活性药物。

10. 当前标准口服药物的治疗。

(1)对于心衰失代偿而出现的AHF患者,应尽力维持改善患者预后和症状的口服药物;
(2)对于新发AHF患者,在血流动力学稳定后应尽力启动标准口服药物治疗。

特别指出β受体阻滞剂可以在除心源性休克的其他AHF病人当中安全的使用。

11. 急诊室出院注意事项。对于病因明确,反复住院的急性失代偿部分的患者,经过急诊治疗,符合以下条件即可出院:

(1)患者主诉病情改善;
(2)静息心率<100bpm;
(3)无站立低血压;
(4)尿量正常;
(5)室内血氧饱和度>95%;
(6)无或中度肾功能恶化。

突出强调急诊快速通道出院后,应立即启动慢性疾病管理计划。而新发生的AHF则不能从急诊直接出院回家,需中间病房进一步明确病因继续治疗,之后再进入管理计划之中。

12. 病房及ICU/CCU治疗要点。注重强调AHF的复杂性和严重性,指出

(1)应将患者安置于可立即开展心肺复苏的场所;
(2)需专科护士护理及医师治疗;
(3)推荐高危患者入CCU专科治疗;
(4)应设置AHF患者的绿色通道。

13. 院内监测注意事项。

(1)患者需每天称重,并有准确的体液平衡记录表;
(2)给予标准无创监测,指标包括脉搏、呼吸频率和血压;
(3)每天检测肾功能及电解质情况;
(4)出院前检测钠尿肽有助于制定出院后治疗方案。

14. 制定了出院标准及高危患者随访计划。

(1)出院标准:
① 出院前24小时血流动力稳定、容量正常、有标准口服药物治疗且肾功能正常;
② 已被告知自我护理相关内容。

(2)随访计划:
① 入组疾病管理系统;
② 出院一周内主治医生随访;
③ 慢性心衰患者纳入心衰随访队列。

15. 心源性休克诊疗要点。

(1)定义为血容量充分,但仍存在低血压(SBP<90mmHg)及低灌注的疾病表现;
(2)对于疑似心源性休克的患者,应立即进行心电图及心脏超声检查;
(3)需动脉导管有创监测;
(4)监测心源性休克患者血流动力学状态的最佳方式尚无定论,包括肺动脉导管;
(5)如果患者无容量负荷过重的证据,推荐补充容量可作为一线疗法;
(6)可使用多巴酚丁胺增加心输出量,可考虑左西孟坦,尤适用于口服β受体阻滞剂的慢性心衰患者;
(7)在收缩压难以维持的情况下,可早期使用血管活性药,去甲肾上腺素优于多巴胺;
(8)及时转诊至专科机构;
(9)不推荐给予主动脉球囊扩张
(10)难治性心源性休克可考虑短期机械循环支持,但需综合考虑患者年龄、合并症及神经系统情况;且暂不确定何种机械循环更优。

总之,这项指南主要通过以上内容详细的对AHF的识别、诊断、急性期治疗、护理、随访等做了充分的描述,是为一个新的有效的“流程图”,对于促进我国AHF的诊治,提供了更有效的指导,值得我们临床借鉴。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1936288, encodeId=4c9b19362881e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Thu Sep 24 04:19:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36232, encodeId=67a33623200, content=一般, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01c61646682, createdName=1ddb9d26m65(暂无匿称), createdTime=Sun Aug 30 12:53:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30636, encodeId=434630636df, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359773, encodeId=970e1359e7331, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373287, encodeId=e32913e328772, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378805, encodeId=ccdc13e880544, content=<a href='/topic/show?id=eae2594251f' target=_blank style='color:#2F92EE;'>#早期管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59425, encryptionId=eae2594251f, topicName=早期管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30020, encodeId=0c32300201a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Tue Jun 30 11:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1936288, encodeId=4c9b19362881e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Thu Sep 24 04:19:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36232, encodeId=67a33623200, content=一般, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01c61646682, createdName=1ddb9d26m65(暂无匿称), createdTime=Sun Aug 30 12:53:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30636, encodeId=434630636df, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359773, encodeId=970e1359e7331, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373287, encodeId=e32913e328772, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378805, encodeId=ccdc13e880544, content=<a href='/topic/show?id=eae2594251f' target=_blank style='color:#2F92EE;'>#早期管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59425, encryptionId=eae2594251f, topicName=早期管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30020, encodeId=0c32300201a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Tue Jun 30 11:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
    2015-08-30 1ddb9d26m65(暂无匿称)

    一般

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1936288, encodeId=4c9b19362881e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Thu Sep 24 04:19:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36232, encodeId=67a33623200, content=一般, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01c61646682, createdName=1ddb9d26m65(暂无匿称), createdTime=Sun Aug 30 12:53:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30636, encodeId=434630636df, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359773, encodeId=970e1359e7331, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373287, encodeId=e32913e328772, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378805, encodeId=ccdc13e880544, content=<a href='/topic/show?id=eae2594251f' target=_blank style='color:#2F92EE;'>#早期管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59425, encryptionId=eae2594251f, topicName=早期管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30020, encodeId=0c32300201a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Tue Jun 30 11:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
    2015-07-04 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1936288, encodeId=4c9b19362881e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Thu Sep 24 04:19:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36232, encodeId=67a33623200, content=一般, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01c61646682, createdName=1ddb9d26m65(暂无匿称), createdTime=Sun Aug 30 12:53:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30636, encodeId=434630636df, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359773, encodeId=970e1359e7331, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373287, encodeId=e32913e328772, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378805, encodeId=ccdc13e880544, content=<a href='/topic/show?id=eae2594251f' target=_blank style='color:#2F92EE;'>#早期管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59425, encryptionId=eae2594251f, topicName=早期管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30020, encodeId=0c32300201a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Tue Jun 30 11:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1936288, encodeId=4c9b19362881e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Thu Sep 24 04:19:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36232, encodeId=67a33623200, content=一般, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01c61646682, createdName=1ddb9d26m65(暂无匿称), createdTime=Sun Aug 30 12:53:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30636, encodeId=434630636df, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359773, encodeId=970e1359e7331, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373287, encodeId=e32913e328772, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378805, encodeId=ccdc13e880544, content=<a href='/topic/show?id=eae2594251f' target=_blank style='color:#2F92EE;'>#早期管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59425, encryptionId=eae2594251f, topicName=早期管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30020, encodeId=0c32300201a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Tue Jun 30 11:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1936288, encodeId=4c9b19362881e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Thu Sep 24 04:19:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36232, encodeId=67a33623200, content=一般, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01c61646682, createdName=1ddb9d26m65(暂无匿称), createdTime=Sun Aug 30 12:53:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30636, encodeId=434630636df, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359773, encodeId=970e1359e7331, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373287, encodeId=e32913e328772, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378805, encodeId=ccdc13e880544, content=<a href='/topic/show?id=eae2594251f' target=_blank style='color:#2F92EE;'>#早期管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59425, encryptionId=eae2594251f, topicName=早期管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30020, encodeId=0c32300201a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Tue Jun 30 11:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1936288, encodeId=4c9b19362881e, content=<a href='/topic/show?id=daa1e60387b' target=_blank style='color:#2F92EE;'>#管理指南#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76038, encryptionId=daa1e60387b, topicName=管理指南)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIUEDhSibBFt8TicgFCCSBtW10SxVJicDpibTCucns8L1YaiaKpibWOkv8hYpJ0LeTVUH1Ab4sfica9bxiccA/132, createdBy=dd282500126, createdName=ms3830150583600765, createdTime=Thu Sep 24 04:19:00 CST 2015, time=2015-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=36232, encodeId=67a33623200, content=一般, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01c61646682, createdName=1ddb9d26m65(暂无匿称), createdTime=Sun Aug 30 12:53:00 CST 2015, time=2015-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30636, encodeId=434630636df, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sat Jul 04 15:45:00 CST 2015, time=2015-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1359773, encodeId=970e1359e7331, content=<a href='/topic/show?id=5aa95229085' target=_blank style='color:#2F92EE;'>#急性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52290, encryptionId=5aa95229085, topicName=急性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373287, encodeId=e32913e328772, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378805, encodeId=ccdc13e880544, content=<a href='/topic/show?id=eae2594251f' target=_blank style='color:#2F92EE;'>#早期管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59425, encryptionId=eae2594251f, topicName=早期管理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Jul 02 02:19:00 CST 2015, time=2015-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=30020, encodeId=0c32300201a, content=哦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19691629579, createdName=zm0805, createdTime=Tue Jun 30 11:52:00 CST 2015, time=2015-06-30, status=1, ipAttribution=)]
    2015-06-30 zm0805

    0

相关资讯

输液致急性心衰原因分析及干预策略

  输液疗法是临床常用的治疗方法,具有药效发挥快、利用率高、液体和药物的输入速度及输入量可控的优点,是临床抢救和治疗患者的重要措施之一。然而,输液疗法也存在被滥用和不合理使用的现象,常可引起输液并发症和不良反应。为此,本期安全输液专题(上)特邀药学专家介绍临床常见的输液所致心衰和静脉炎的原因分析和干预策略   在临床上,虽然因输液引起急性心衰的病例并不多见,但一旦出现,常会严重影响患者生活质量,

Rolofylline(一种腺苷A1受体拮抗剂)对急性心衰作用无效

  背景 在急性心力衰竭病人中,与不良转归相关的肾功能恶化经常发生。实验研究和临床研究提示,腺苷介导的逆调节反应有可能与之相关。我们检验了下列假说:在急性心力衰竭病人中,使用rolofylline(一种腺苷A1受体拮抗剂)将改善(病人的)呼吸困难,降低肾功能恶化的危险,并导致更加有利的临床病程。   方法 我们进行了一项多中心、双盲、安慰剂对照临床试验,纳入因急性心力衰竭伴肾功能损害而住院的病

输液致急性心衰原因分析、干预策略及病例分享

  输液疗法是临床常用的治疗方法,具有药效发挥快、利用率高、液体和药物的输入速度及输入量可控的优点,是临床抢救和治疗患者的重要措施之一。然而,输液疗法也存在被滥用和不合理使用的现象,常可引起输液并发症和不良反应。为此,本期安全输液专题(上)特邀药学专家介绍临床常见的输液所致心衰和静脉炎的原因分析和干预策略   在临床上,虽然因输液引起急性心衰的病例并不多见,但一旦出现,常会严

JAMA:急性心衰合并肾功能不全肾脏优化策略评估研究讨论

2013年12月,来自美国梅奥诊所医学中心的Chen博士等在JAMA杂志上发表了题为“Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial.”的文章,即ROSE研究的研究结果。研究表明在

Lancet:重组人松弛素-2Serelaxin治疗急性心力衰竭

  背景  重组人松弛素-2 serelaxin是一种血管活性肽激素,可产生多种生物学和血流动力学效应。初步研究显示,serelaxin治疗急性心力衰竭患者是安全的且耐受性良好,同时可见积极的临床转归征象。RELAX-AHF试验对如下假说进行了检验:接受serelaxin治疗的患者呼吸困难缓解程度大于接受标准治疗和安慰剂治疗的患者。   方法  RELAX-AHF是一项国际性